Skip to main content
. 2021 Sep 9;6(5):100261. doi: 10.1016/j.esmoop.2021.100261

Figure 1.

Figure 1

CONSORT diagram of study population: metastatic prostate cancer patients treated with ADT and abiraterone or enzalutamide.

ADT, androgen deprivation therapy; CV, cardiovascular; MI, myocardial infarction.

∗∗Fourteen patients were excluded who had survival time (time interval between date of outcome, disenrollment, or end of study and start date of abiraterone or enzalutamide start date less than zero) and five patients were excluded who started both enzalutamide and abiraterone on the same day.